Higher Serum Lysophosphatidic Acids Predict Left Ventricular Reverse Remodeling in Pediatric Dilated Cardiomyopathy

Area of Science:

• Cardiology
• Metabolomics
• Pediatric Medicine

Background:

• Pediatric dilated cardiomyopathy (PDCM) has a variable prognosis, with left ventricular reverse remodeling (LVRR) indicating a favorable outcome.
• Lipid metabolism disturbances are linked to cardiac function changes, but their role in PDCM and LVRR is understudied.

Purpose of the Study:

• To investigate the association between lipidomics data and LVRR in pediatric patients with dilated cardiomyopathy.
• To identify specific lipid biomarkers for predicting LVRR and to develop a predictive risk score.

Main Methods:

• Utilized targeted lipidomics on 540 lipids from the prospective China-AOCC study (discovery and validation sets).
• Employed OPLS-DA and random forest analysis for candidate lipid screening.
• Developed a risk score based on significant lysophosphatidic acids (LysoPA) and assessed its predictive value in Cox regression models and AUC analysis.

Main Results:

• Four lysophosphatidic acids (LysoPA 16:0, 18:2, 18:1, 18:0) were significantly associated with LVRR after adjusting for clinical factors.
• A LysoPA score combining these four lipids improved the prediction of LVRR.
• The addition of the LysoPA score to the LVEDD z-score significantly increased the area under the curve (AUC) for LVRR prediction in both discovery and validation sets.

Conclusions:

• Serum LysoPA levels are predictive of LVRR in pediatric dilated cardiomyopathy patients.
• A combined LysoPA score and LVEDD z-score can enhance the prediction of LVRR, aiding in patient prognosis and monitoring therapeutic responses.